CN102895247A - Application of Houttuynoid B to medicament for treating oophoroma - Google Patents
Application of Houttuynoid B to medicament for treating oophoroma Download PDFInfo
- Publication number
- CN102895247A CN102895247A CN2012104170939A CN201210417093A CN102895247A CN 102895247 A CN102895247 A CN 102895247A CN 2012104170939 A CN2012104170939 A CN 2012104170939A CN 201210417093 A CN201210417093 A CN 201210417093A CN 102895247 A CN102895247 A CN 102895247A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- medicament
- application
- oophoroma
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Houttuynoid B to preparation of a medicament for treating human oophoroma, belonging to the technical field of novel medicament applications. As proved by in-vitro MTT (Methyl Thiazolyl Tetrazolium) antitumor activity evaluation, the Houttuynoid B has remarkable inhibiting effects on the growth of human oophoroma cell strains HO-8910, HOC1 (Hepatic Oval Cell 1) and OVAC. Therefore, the Houttuynoid B can be used for preparing a medicament for resisting oophoroma, and has good development and application prospects. The application of the Houttuynoid B to preparation of a medicament for treating human oophoroma related to the invention is disclosed for the first time. A framework type belongs to a brand new framework type, and the inhibiting activity of the Houttuynoid B on human oophoroma cells is unpredictably high.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid B, relate in particular to the application of Houttuynoid B in the preparation ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid B that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid B that the present invention relates in preparation treatment ovarian cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid B in the preparation ovarian cancer resistance medicament, and the structural formula of Houttuynoid B is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid B also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50Value is respectively 0.22 ± 0.07 μ M, 0.31 ± 0.07 μ M and 0.61 ± 0.06 μ M.Therefore, Houttuynoid B can for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Houttuynoid B that the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid B to human oophoroma cell line's growth inhibited effect
1. method: the cell that is in the growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid B has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This chemical compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50Value is respectively: 0.22 ± 0.07 μ M, 0.31 ± 0.07 μ M and 0.61 ± 0.06 μ M.
Shown that by above-described embodiment Houttuynoid B of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove that thus Houttuynoid B of the present invention has the ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
1.Houttuynoid the application of B in treatment ovarian cancer medicine, described compound H outtuynoid B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104170939A CN102895247A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B to medicament for treating oophoroma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104170939A CN102895247A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B to medicament for treating oophoroma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102895247A true CN102895247A (en) | 2013-01-30 |
Family
ID=47567933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104170939A Pending CN102895247A (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B to medicament for treating oophoroma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102895247A (en) |
-
2012
- 2012-10-27 CN CN2012104170939A patent/CN102895247A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| SHAO-DAN CHEN等: "Houttuynoids A E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102861099A (en) | Application of Houttuynoid D in medicine for treating endometrial cancer | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma | |
| CN102872073A (en) | Application of Houttuynoid C in drugs for treating ovarian cancer | |
| CN102861086A (en) | Application of Houttuynoid E in medicine for treating ovarian cancer | |
| CN102861046A (en) | Application of Houttuynoid A in ovarian cancer treatment medicine | |
| CN102872151A (en) | Application of Houttuynoid B in medicament for treating nasopharyngeal cancer | |
| CN102895249A (en) | Application of Houttuynoid E to medicament for treating prostatic carcinoma | |
| CN102872125A (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872139A (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861096A (en) | Application of Houttuynoid E in medicine for treating cervical cancer | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102872088A (en) | Application of Houttuynoid D in medicines for treating nasopharyngeal carcinoma | |
| CN102872068A (en) | Application of Houttuynoid E in drugs for treating colorectal cancer | |
| CN102872072A (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130130 |